Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 5/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595494 | 0.91 | AQP1 (0.36) | AQP1HTR7HTR1APRKAB2PRKAG1 | |
| SCHEMBL4649843 | 0.87 | HTR1A (0.40) | AQP1HTR2AHTR2CHTR7HTR1A | |
| SCHEMBL4596978 | 0.84 | AQP1 (0.47) | AQP1HTR2AHTR2C | |
| SCHEMBL4596281 | 0.81 | GABRA1 (0.34) | AQP1HTR2AHTR2CHTR7HTR1A | |
| SCHEMBL4597588 | 0.81 | HTR7 (0.43) | AQP1HTR7HTR1APRKAB2PRKAG1 | |
| SCHEMBL4596735 | 0.81 | AQP1 (0.47) | AQP1 | |
| SCHEMBL4595614 | 0.81 | AQP1 (0.62) | AQP1NOS3 | |
| SCHEMBL4596981 | 0.81 | PARP1 (0.48) | AQP1HTR7HTR1A | |
| SCHEMBL4596563 | 0.81 | HTR1A (0.38) | HTR2AHTR2CHTR2BHTR7HTR1A | |
| SCHEMBL6047926 | 0.81 | PRKAB2 (0.39) | AQP1NOS3HTR7HTR1APRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1874292-A2 | METHODS FOR MODULATING BLADDER FUNCTION | Wyeth (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007030150-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116169-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |